Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28902163 | 0.83 | PTGER4 (0.48) | PTGER4PHGDHPTGDR | |
| SCHEMBL1956244 | 0.83 | PTGER4 (0.48) | PTGER4PHGDHPTGDR | |
| SCHEMBL197366 | 0.81 | PTGER4 (0.49) | PTGER4PTGER2PTGDR | |
| SCHEMBL28477223 | 0.73 | PTGER4 (0.56) | PTGER4PTGER2PHGDHPTGDR | |
| SCHEMBL1956758 | 0.73 | PTGER4 (0.56) | PTGER4PTGER2PHGDHPTGDR | |
| SCHEMBL10122169 | 0.71 | PTGER4 (0.80) | PTGER4PTGER2PHGDH | |
| SCHEMBL28933083 | 0.70 | PTGER4 (0.69) | PTGER4 | |
| SCHEMBL28933081 | 0.70 | PTGER4 (0.69) | PTGER4 | |
| SCHEMBL881502 | 0.69 | PTGER4 (0.77) | PTGER4PTGER2PTGDR | |
| SCHEMBL9900432 | 0.69 | ACACB (0.62) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079013-A1 | Heterobicyclic Carboxylic Acids and Salts Thereof | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2021-03-18 | — | — | US | claimed |
| US-20200352906-A1 | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2020-11-12 | — | — | US | claimed |
| JP-2012500211-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | claimed |
| EP-2320906-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Beta Pharma Canada Inc. (CA) | 2011-05-18 | — | — | EP | claimed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | Foshan Ionova Biotherapeutics Co., Inc. (CN) | 2025-03-04 | — | — | US | disclosed |
| CN-111936502-B | Heterobicyclic carboxylic acids and salts thereof | 深圳市原力生命科学有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117643587-A | Heterobicyclic carboxylic acids for the treatment of cancer | 深圳市原力生命科学有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20210079013-A1 | Heterobicyclic Carboxylic Acids and Salts Thereof | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079013-A1 | Heterobicyclic Carboxylic Acids and Salts Thereof | PTGER4, PTGER1, GPR4 | PTGER4 1/4885PTGER2 9/4885PHGDH 1086/4885 |
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | PTGER4, PTGER1, GPR4 | PTGER4 1/4885PTGER2 9/4885PHGDH 1086/4885 |
| US-20200352906-A1 | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PHGDH 579/4885 |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PHGDH 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.